These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 33450164)

  • 1. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease.
    Clark D; Sheppard J; Brady TC
    J Ocul Pharmacol Ther; 2021 May; 37(4):193-199. PubMed ID: 33450164
    [No Abstract]   [Full Text] [Related]  

  • 2. Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease.
    Clark D; Tauber J; Sheppard J; Brady TC
    Am J Ophthalmol; 2021 Jun; 226():22-31. PubMed ID: 33529588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement.
    Mandell KJ; Clark D; Chu DS; Foster CS; Sheppard J; Brady TC
    J Ocul Pharmacol Ther; 2020 Dec; 36(10):732-739. PubMed ID: 32955967
    [No Abstract]   [Full Text] [Related]  

  • 4. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease.
    Schmidl D; Szalai L; Kiss OG; Schmetterer L; Garhöfer G
    Adv Ther; 2021 Apr; 38(4):1975-1986. PubMed ID: 33710587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease.
    McMullin D; Clark D; Cavanagh B; Karpecki P; Brady TC
    Clin Ophthalmol; 2021; 15():3889-3900. PubMed ID: 34588761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
    Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
    Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of corneal nerve density on the response to treatment in dry eye disease.
    Kheirkhah A; Dohlman TH; Amparo F; Arnoldner MA; Jamali A; Hamrah P; Dana R
    Ophthalmology; 2015 Apr; 122(4):662-8. PubMed ID: 25542519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial.
    Clark D; Cavanagh B; Shields AL; Karpecki P; Sheppard J; Brady TC
    Am J Ophthalmol; 2021 Oct; 230():60-67. PubMed ID: 33945820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China.
    Dong Y; Wang S; Cong L; Zhang T; Cheng J; Yang N; Qu X; Li D; Zhou X; Wang H; Lee M; Wang M; Chen S; Ousler GW; Chen X; Xie L
    Int Ophthalmol; 2022 Aug; 42(8):2459-2472. PubMed ID: 35192105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the clinical effects of carbomer-based lipid-containing gel and hydroxypropyl-guar gel artificial tear formulations in patients with dry eye syndrome: a 4-week, prospective, open-label, randomized, parallel-group, noninferiority study.
    Wang TJ; Wang IJ; Ho JD; Chou HC; Lin SY; Huang MC
    Clin Ther; 2010 Jan; 32(1):44-52. PubMed ID: 20171410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.
    Akpek EK; Wirta DL; Downing JE; Tauber J; Sheppard JD; Ciolino JB; Meides AS; Krösser S
    JAMA Ophthalmol; 2023 May; 141(5):459-466. PubMed ID: 37022717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.
    Amparo F; Dastjerdi MH; Okanobo A; Ferrari G; Smaga L; Hamrah P; Jurkunas U; Schaumberg DA; Dana R
    JAMA Ophthalmol; 2013 Jun; 131(6):715-723. PubMed ID: 23599118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
    Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
    Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
    Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
    Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease.
    Taylor M; Ousler G; Torkildsen G; Walshe C; Fyfe MCT; Rowley A; Webber S; Sheppard JD; Duggal A
    Clin Ophthalmol; 2019; 13():261-275. PubMed ID: 30858682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Sodium Hyaluronate/chondroitin Sulfate Preservative-free Ophthalmic Solution in the Treatment of Dry Eye: A Clinical Trial.
    Belalcázar-Rey S; Sánchez Huerta V; Ochoa-Tabares JC; Altamirano Vallejo S; Soto-Gómez A; Suárez-Velasco R; García-Félix F; Baiza-Durán L; Olvera-Montaño O; Muñoz-Villegas P
    Curr Eye Res; 2021 Jul; 46(7):919-929. PubMed ID: 33289602
    [No Abstract]   [Full Text] [Related]  

  • 20. A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study.
    Sheppard JD; Wirta DL; McLaurin E; Boehmer BE; Ciolino JB; Meides AS; Schlüter T; Ousler GW; Usner D; Krösser S
    Cornea; 2021 Oct; 40(10):1290-1297. PubMed ID: 34481407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.